GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mizuho Medy Co Ltd (TSE:4595) » Definitions » COGS-to-Revenue

Mizuho Medy Co (TSE:4595) COGS-to-Revenue : 0.29 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mizuho Medy Co COGS-to-Revenue?

Mizuho Medy Co's Cost of Goods Sold for the three months ended in Mar. 2024 was 円786 Mil. Its Revenue for the three months ended in Mar. 2024 was 円2,742 Mil.

Mizuho Medy Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.29.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mizuho Medy Co's Gross Margin % for the three months ended in Mar. 2024 was 71.33%.


Mizuho Medy Co COGS-to-Revenue Historical Data

The historical data trend for Mizuho Medy Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mizuho Medy Co COGS-to-Revenue Chart

Mizuho Medy Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.34 0.25 0.20 0.27

Mizuho Medy Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.29 0.22 0.28 0.29

Mizuho Medy Co COGS-to-Revenue Calculation

Mizuho Medy Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2915.687 / 10989.735
=0.27

Mizuho Medy Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=786 / 2742
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mizuho Medy Co  (TSE:4595) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mizuho Medy Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 786 / 2742
=71.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Mizuho Medy Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mizuho Medy Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mizuho Medy Co (TSE:4595) Business Description

Traded in Other Exchanges
N/A
Address
4 Fujinoki-Machi, Saga Prefecture, Tosu, JPN, 841-0048
Mizuho Medy Co Ltd engages in research and development, manufacture and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.

Mizuho Medy Co (TSE:4595) Headlines

No Headlines